A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma

Margaret A. Fischl, Dianne M. Finkelstein, Weili He, William G. Powderly, Pierre L. Triozzi, Roy T. Steigbigel

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

To assess safety, antitumor response, and immunological and virological activity of interferon-α2a and zidovudine combination therapy in patients with AIDS-related Kaposi's sarcoma, we conducted an open-label, Phase II, multicenter study. Sixty-three patients with biopsy-proven Kaposi's sarcoma and no previous interferon-α therapy received zidovudine 600 mg/day and interferon-α2a 18 × 106 U/day. The median duration of follow-up was 49 weeks. Of 62 evaluable patients, 25 (40%; 95% confidence interval, 0.28-0.52) showed a complete (26%) or partial (15%) antitumor response. Eight of 30 patients (27%) with <100 CD4 cells/mm3 and 17 of 32 patients (53%) with ≥100 CD4 cells/mm3 had a response. The median time to response was 36 weeks. Of the 25 patients with a response, four developed tumor progression. The median duration of response was 22.4 weeks. Eight patients (13%) developed another AIDS-defining event and 13 (21%) died. The major toxicities included anemia (16%), neutropenia (27%), elevated serum transaminases (16%), weight loss (16%), malaise (14%), fatigue (14%), fever (10%), and headache (6%). Therapy with intermediate-dose interferon-α2a and zidovudine resulted in tumor regression in patients with AIDS-related Kaposi's sarcoma who had a wide range of CD4 cell counts; this therapy was relatively well tolerated.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume11
Issue number4
DOIs
StatePublished - Jan 1 1996

    Fingerprint

Keywords

  • Interferon-α
  • Kaposi's sarcoma
  • Zidovudine

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Immunology and Allergy

Cite this